Topic: Rituxan
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending experimental rheumatoid arthritis and lupus treatment ocrelizumab after deaths following its use, casting doubt over its future.Roche and Biogen stopped using the experimental drug for the ...
FDA rejects expanded use of rheumatoid arthritis drug RituxanThe Food and Drug Administration has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec ...
The cancer drug Rituxan may offer the first new treatment approved for lupus in 50 years, suggests a small study by U.K. researchers at Imperial College London. After treatment with Rituxan, 60 percent showed significant signs of improvement, the researchers found. Rituxan ...
BIIB) announced today that a Phase III study of Rituxan? (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. "We are disappointed that Rituxan did ...
Rituxan, sold by Genentech and Biogen Idec, targets immune system cells called B-cells and is already approved for rheumatoid arthritis. The study was supported by Biogen and Genentech, and Hauser has received grant support from Biogen.. Rituxan needs more study before it ...
Will Rituxan work for lupus?. Results of a Rituxan trial in lupus are due in a few weeks, Dow Jones Newswires reports. Even if they're positive, they may not be enough to win approval for the drug - but they could drive ...
Preliminary results were released today from a late-stage clinical trial of Rituxan (rituximab) for the treatment of lupus. Rituxan is approved by the U.S. Food and Drug Administration for the treatment of non-Hodgkin's lymphoma, and was more recently approved, in combination with ...
BIIB) announced today that a Phase II/III study of Rituxan (rituximab) for systemic lupus erythematosus (SLE, commonly called lupus) did not meet its primary endpoint defined as the proportion of Rituxan treated patients who achieved a major clinical response (MCR) or partial ...
Will Rituxan work for lupus?. Results of a Rituxan trial in lupus are due in a few weeks, Dow Jones Newswires reports. Even if they're positive, they may not be enough to win approval for the drug - but they could drive ...
Today it is clear that treating cancer with monoclonal antibodies is one of the greatest advancements in oncology. Just over a decade ago, the approval of Rituxan marked the birth of a multi-billion dollar market, as 8 additional antibodies have since joined ...
From Around the Web
Video Gallery
-
Mechanism of Action Animation for Rituxan ...
Award-winning Mechanism of Action Animation (MOA) Video produced by NIA ...2009-10-14 -
Serious Infection in Lupus Patients Treated ...
FDA is alerting health care professionals and patients about new ...2008-06-05 -
Rituximab (Rituxan)
A brief video describing the use of rituximab also known ...2011-06-12
